US Stock MarketDetailed Quotes
SGMO Sangamo Therapeutics
- 2.710
- +0.010+0.37%
Close Nov 12 16:00 ET
- 2.530
- -0.180-6.64%
Post 19:19 ET
564.28MMarket Cap-1963P/E (TTM)
2.860High2.440Low9.09MVolume2.530Open2.700Pre Close24.73MTurnover4.80%Turnover RatioLossP/E (Static)208.22MShares3.17952wk High23.77P/B513.78MFloat Cap0.30452wk Low--Dividend TTM189.59MShs Float51.375Historical High--Div YieldTTM15.56%Amplitude0.291Historical Low2.719Avg Price1Lot Size
Sangamo Therapeutics Stock Forum
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$ Third Quarter 2024 Financial Results
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
1
5
$Sangamo Therapeutics (SGMO.US)$
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...
1
$Sangamo Therapeutics (SGMO.US)$
Looking like it's coming together.
10 dollar target from HCW today. GLTA
Looking like it's coming together.
10 dollar target from HCW today. GLTA
4
2
$Sangamo Therapeutics (SGMO.US)$ .. drop to below 1.5.. sell now later buy once drop down.
1
$Sangamo Therapeutics (SGMO.US)$ New 52 Wk high🥂💸
1
2
$Sangamo Therapeutics (SGMO.US)$ Go baby go!
1
$Sangamo Therapeutics (SGMO.US)$
Check this out.... Cost of ERT therapy for lifetime for a Fabry patient. Dutch study. The numbers will surprise you!!!
https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-29
Check this out.... Cost of ERT therapy for lifetime for a Fabry patient. Dutch study. The numbers will surprise you!!!
https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-29
$Sangamo Therapeutics (SGMO.US)$
price consolidating. some people taking profits. Fabry deal when announced should put us over $2 I think. Still holding full position at 0 .68 patiently holding for a big payday next year sometime I think.
price consolidating. some people taking profits. Fabry deal when announced should put us over $2 I think. Still holding full position at 0 .68 patiently holding for a big payday next year sometime I think.
2
$Sangamo Therapeutics (SGMO.US)$ comon Fabry deal and Hemo
2
3
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
WillLaw : Let's go baby, listening to webcast, very promising, multiple BLA's for 2025, milestone payments, accelerated FDA approval.
Trytosaveabit OP WillLaw : Indeed! Lotsa good catalyst coming over the next 6/12 months! GL and big profits to ya
One One One One : why drop then
Trytosaveabit OP One One One One : Not enough after market volume to keep shorts from pushing it down!
Trytosaveabit OP One One One One : Also I just seen they filed a shelf offering! I’m sure that also contributed to the fall.